The recombinant plasma protein therapeutics market is set to grow from US$ 8,435.3 Mn in 2021 to US$ 17,231.07 Mn in 2030 expanding at an annual growth rate of 8.3% during the forecast period from 2023 to 2030. According to World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer with some form of bleeding disorder, 75% of them gain inadequate treatment and remain undiagnosed.
"Lack of blood borne transmission disease and less severe effects in comparison to desmopressin popularizes recombinant coagulation factor VIII in treating hemophilia A"
Recombinant coagulation factor VIII is leading the drug class segment for recombinant plasma protein therapeutics market. It is preferred over human plasma derive products to avoid potential transmission of blood borne infections. It is replacing desmopressin in treating mild hemophilia due to less adverse effects. Recombinant factor IX will gain growth momentum in the near future owing to recent FDA approval of Rebinyn (Novo Nordisk) for long term treatment of hemophilia B.
"Ability to adapt growth conditions in serum free suspension, powerful gene amplification system and capacity for post translational modification drive the Chinese hamster ovary cell lines in recombinant protein synthesis"
Since last 2 decades Chinese hamster ovarian cell lines have gained immense popularity over other cell lines such as baby hamster kidney cell lines and human embryonic kidney cell lines. Its ability to adapt growth conditions in serum free suspension, powerful gene amplifications and capacity for post translational modification proves its popularity as the most demanding cell line over others in recombinant protein syntheis.
"High prevalence rate and 70 % of the diagnosed patients reported to suffer with severe form drive Hemophilia A market growth"
Hemophilia A also known as clotting factor VIII deficiency or classical hemophilia is currently leading the indication segment for recombinant plasma protein therapeutics market. It has a high prevalence rate of 1 in 5000 people with approximately 70% diagnosed patients reported to be suffering with severe form of hemophilia A. The other type is Hemophilia B which is less common form with an occurrence rate of 1 in 25,000 people, it is caused due to lack of clotting factor IX. Von Willebrand disease is keen to register impressive growth in the near future due to high occurrence in blood group O type and rising public health awareness.
"Rising prevalence of Hemophilia A and presence of a comprehensive network of federally funded treatment centers for hemophilia drive market growth in North America"
North America is reigning the regional segment for recombinant plasma protein therapeutics market with a share of 40%. The chief factors controlling its market growth are rising prevalence of hemophilia A, according to the research findings of Center for Disease Control and Prevention (CDC), approximately 20,000 people are suffering with hemophilia in the United States. The existence of a comprehensive network of federally funded treatment centers for hemophilia cater to the medical aid of 70% patients with blood clotting disorders in North America region. Europe accounts for 30% market share due to increasing new born babies suffering with hemophilia. According to European Medical Agency (EMA) research findings annually 400 babies are born with hemophilia. Domicile of major players such as Novo Nordisk A/S, Bayer AG, Shire, Plc etc. bolster the market growth in Europe. Asia Pacific holds 20% market growth and is keen to register rapid growth during the forecast period owing to adoption of recombinant technology for protein synthesis and large patient pool suffering with blood clotting disorders.
Biotechnology companies manufacturing recombinant plasma proteins are Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Recombinant Plasma Protein Therapeutics market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Class
| |
Cell Line
| |
Indication
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
